Hologic’s Latest Product Pipeline & Sales Shakeup—Is This the Start of a Multi-Year Rally? 

Hologic, Inc., a prominent player in healthcare solutions for women’s health, reported its financial results for the third quarter of fiscal 2025. The results were a mixed bag with both positive advancements and some challenges that the company aimed to address. Hologic’s total revenue for the third quarter was $1.024 billion, representing a modest year-over-year growth of 0.4%, which exceeded the guidance by approximately $14 million. This growth was attributed to solid performances in specific business areas, namely Diagnostics and an improvement in the Breast Health business, along with steady contributions from the Surgical and Skeletal Health segments. Non-GAAP earnings per share also saw a slight increase of 1.9% to $1.08, surpassing the high end of the company’s guidance range by $0.01. These results reflect Hologic’s efforts to navigate previous financial headwinds.